miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells
Rounak Nassirpour(Pfizer (United States)), Min-Jean Yin(Maxygen (United States))
Cited by 93
Related Papers
Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
|Journal of Medicinal Chemistry|2016|93